Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

BillionerOfKing Apr. 29 at 5:10 PM

$ABOS Current Stock Price: $2.37 Contracts to trade: $2.5 ABOS May 15 2026 Call Entry: $0.46 Exit: $0.71 ROI: 55% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Adamchristlover Apr. 22 at 10:39 PM

$CRBU $HUMA $ABOS Nice seeing you Jack I am holding HUMA and CRBU

0 · Reply

jacksparo Apr. 22 at 5:36 PM

$CRBU From my email and it’s doing good so far since then $HUMA In my Live Biotech group still holding some . $ABOS Still holding!

0 · Reply

jacksparo Apr. 22 at 2:06 AM

$IBRX $CADL $SLS $ABOS $OCGN Today the market was under pressure. We noticed that in multiple stocks. I would say we are still in a highly volatile zone . It could change by Thursday… Regardless I have plans and I am not seeing a legit reason to be worried!

1 · Reply

loveusa1988 Apr. 21 at 1:42 PM

$OCGN $AKBA $ABOS $GEVO $LAES 100% well said Jack!

2 · Reply

kil0gho5t Apr. 21 at 1:39 PM

$ABOS $AKBA $GEVO $LAES $OCGN dont give these furus your money. Funny how they call everyone uneducated whilst his plays are getting smoked. You are not educated on market mechanics you are educated in promoting and scamming innocent people.

1 · Reply

SuperchargedSaleenLife04 Apr. 21 at 1:34 PM

$ABOS $AKBA $GEVO $LAES $OCGN thank you JackSparo from me and AdamChristLover

1 · Reply

jacksparo Apr. 21 at 1:26 PM

$OCGN $AKBA $ABOS $GEVO $LAES Let's stay focused and block out the uneducated noise around us. I am here to make money, and seriously, I care 0 or even less for anyone who comes and says, " Oh, Jack is spamming, " " Oh, Jack got people to pump him, " or " Oh, Jack is looking for subscribers. If you have been trading since 2002 and you traded using landline calls, where you had to wait 45 minutes for each trade to be filled, then you will know the value of your time and how important it is to stay focused in this market!

0 · Reply

jacksparo Apr. 20 at 1:20 PM

$SLS $CADL $NRXP $OCGN $ABOS Let us see what this week will bring. I will be taking my important notes and sharing my live updates ( in my Live Biotech Group ). May, June, and July are among the most important months in some micro and small-cap biotech stocks! Pay attention to that! I already shared a new trading plan for NRXP last night in my email group (entry, exit, and SL with a full plan)!

1 · Reply

luminouslumens Apr. 17 at 2:31 PM

$ABOS 🧐

0 · Reply

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 4 weeks ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Mar 19, 2026, 4:00 PM EDT - 5 weeks ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

Mar 18, 2026, 11:00 AM EDT - 6 weeks ago

Acumen Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

Mar 16, 2026, 6:30 AM EDT - 6 weeks ago

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Mar 10, 2026, 4:00 PM EDT - 7 weeks ago

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Nov 12, 2025, 8:00 AM EST - 6 months ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 11, 2025, 4:40 PM EST - 6 months ago

Acumen Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Sep 5, 2025, 9:10 AM EDT - 8 months ago

Acumen Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 3:15 PM EDT - 8 months ago

Acumen Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 26, 2025, 4:00 PM EDT - 8 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Acumen Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 15, 2025, 7:00 AM EDT - 10 months ago

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 10 months ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 14, 2025, 11:15 AM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 3:30 PM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: Stifel’s 2025 Virtual CNS Forum

Mar 18, 2025, 8:48 AM EDT - 1 year ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 17, 2025, 12:30 PM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: UBS Virtual CNS Day 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Dec 3, 2024, 3:00 PM EST - 1 year ago

Acumen Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Acumen Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:15 PM EST - 1 year ago

Acumen Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: Bank of America CNS Therapeutics Virtual Conference

Oct 2, 2024, 10:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: R&D Day 2024

Sep 30, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 10, 2024, 1:30 PM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 20, 2024, 12:30 PM EDT - 2 years ago

Acumen Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 11:55 AM EDT - 2 years ago

Acumen Pharmaceuticals Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 26, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 19, 2024, 12:00 PM EDT - 2 years ago

Acumen Pharmaceuticals Transcript: Stifel Virtual 2024 CNS Day

Mar 12, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 2 years ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 11, 2024, 1:30 PM EST - 2 years ago

Acumen Pharmaceuticals Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 4, 2024, 4:15 PM EST - 2 years ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 10:00 AM EST - 2 years ago

Acumen Pharmaceuticals Transcript: UBS Biopharma Conference 2023

Nov 6, 2023, 4:01 PM EST - 2 years ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Nov 6, 2023, 7:30 AM EST - 2 years ago

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Nov 2, 2023, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 6, 2023, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q2 2023

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 17, 2023, 8:00 AM EDT - 3 years ago

Acumen Pharmaceuticals Transcript: Study Result

May 9, 2023, 8:00 AM EDT - 3 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q1 2023

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2022

Nov 14, 2022, 4:30 PM EST - 3 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2022

BillionerOfKing Apr. 29 at 5:10 PM

0 · Reply

Adamchristlover Apr. 22 at 10:39 PM

$CRBU $HUMA $ABOS Nice seeing you Jack I am holding HUMA and CRBU

0 · Reply

jacksparo Apr. 22 at 5:36 PM

$CRBU From my email and it’s doing good so far since then $HUMA In my Live Biotech group still holding some . $ABOS Still holding!

0 · Reply

jacksparo Apr. 22 at 2:06 AM

1 · Reply

loveusa1988 Apr. 21 at 1:42 PM

$OCGN $AKBA $ABOS $GEVO $LAES 100% well said Jack!

2 · Reply

kil0gho5t Apr. 21 at 1:39 PM

1 · Reply

SuperchargedSaleenLife04 Apr. 21 at 1:34 PM

$ABOS $AKBA $GEVO $LAES $OCGN thank you JackSparo from me and AdamChristLover

1 · Reply

jacksparo Apr. 21 at 1:26 PM

0 · Reply

jacksparo Apr. 20 at 1:20 PM

1 · Reply

luminouslumens Apr. 17 at 2:31 PM

$ABOS 🧐

0 · Reply

RoBERTTR87 Apr. 13 at 12:54 AM

$SLS $AKBA $OCGN $IBRX $ABOS

0 · Reply

jacksparo Apr. 10 at 10:24 PM

$SLS $AKBA $OCGN $IBRX $ABOS I will be doing a full thorough review this weekend about everything happened this week here so I can complete my assessment plus my update about them! Highly volatile week in some biotech but overall not seeing a major issue yet!

3 · Reply

outlawinvestor1 Apr. 10 at 7:39 AM

$ABOS

0 · Reply

Billianas Apr. 6 at 7:33 PM

$ABOS

0 · Reply

SmartMoneyTradez Apr. 6 at 2:59 PM

$FF $ABOS $CRNC all green

0 · Reply

jacksparo Apr. 6 at 1:46 PM

$SLS $IBRX $ATOS $ABOS $OCGN Lets us see what today and this week will bring in ✅📈✅📈! I will taking all my needed notes for any possible updates 📈📈!

0 · Reply

SirBensonbot Apr. 3 at 12:27 AM

$ABOS long

0 · Reply

SmartMoneyTradez Apr. 2 at 11:37 PM

$FF $ABOS $CRNC day 2 multis

0 · Reply

Billianas Apr. 2 at 4:25 PM

$ABOS this one is definitely going under 1$ next few weeks

1 · Reply

jacksparo Apr. 2 at 2:22 PM

$SLS $IBRX $OCGN $NRXP $ABOS No panic at all , instead I am watching every single possible opportunity. The market can do whatever it wants. As long as my money in my pocket and I should be fine. Let’s us see how today goes! Remember no market tomorrow!

0 · Reply

outlawinvestor1 Mar. 31 at 1:11 PM

$ABOS trading back down at approx fully diluted cash now + ra cap investment 2 weeks ago. i'm going to buy now.

0 · Reply

ForestFoxes Mar. 28 at 5:53 AM

$ANVS and her CEO, Dr. Maccecchini, brought about these two events via her dishonest business dealings and lack of ethics, IMO: 1️⃣ "Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE" https://www.annovisbio.com/press-release/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse 2️⃣ Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements https://s3.amazonaws.com/sec.irpass.cc/2990/0001104659-26-034611.pdf Warning to #MarkGuerin as Dr. Maccecchini likes to brag about firing her former CFOs to people she chats with. You will notice comments such as those posted on Stocktwits (here) such as: - "The CFO's employment history looks very suspicious?" - "Maybe she is blaming share slide on CFO." - "Why not dump them ... none so far have been useful in obtaining any funding. Rather let a non-performer go ... thy all had runs of 1 year here with zero cash influx." I know Dr. Maccecchini must have lied to Mark Guerin to induce his employment. Also, the comments blaming you and other former CFOs is very likely from Dr. Maccecchini making such innuendos to others. Dr. Maccecchini make false statements in her SEC filings as she told me she fired two of her former CFOs yet her SEC filings did NOT reflect these facts. I have also witnessed Dr. Maccecchini make material alterations to investment publications w/o required SEC filings. Dr. Maccecchini likely fights with all of her CFOs about her willfulness to ignore SEC filing protocols #SEC. Tagging $CGTX $ABOS $FLNA and $AVXL investors to warn them.

3 · Reply

Market Cap	177.68M
Revenue (ttm)	0.00
Net Income (ttm)	-121.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.44

Volume	279,400
Avg Vol	601,248
Day's Range	N/A - N/A
Shares Out	72.23M
Stochastic %K	2%
Beta	0.33
Analysts	Strong Sell
Price Target	$7.50